*Department of Family Medicine
†School of Medical Biological Sciences
§Department of Epidemiology and Biostatistics, School of Community and Rural Health, University of Texas Health Science Center at Tyler
‡Trauma Services, The University of Texas Health Science Center, University of Texas Health East Texas, Tyler, TX
S.I. is supported in part by NIH R01 HL130402. S.I., Florova G, PhD, and Komissarov A.A, PhD, Department of Cellular and Molecular Biology, The University of Texas Health Science Center, Tyler, TX.
Disclosure: S.I.: serves as a Founder and Chief Scientific Officer of LTI and as a member of the Board of Directors of LTI, which provided funding for the preparation of the drug product and for the trial. He has an equity position (first-tier conflict of interest) in the company, as does the University of Texas Horizon Fund and the UTHSCT. He has a conflict-of-interest plan acknowledging and managing these declared conflicts of interest through the UTHSCT and the UT System. He is an inventor on a patent (USPTO 7332469) held by the UT Board of Regents and licensed to LTI. The remaining authors declare that they have no conflicts of interest.
Address correspondence to: Alan Cook, MD, MS, FACS, University of Texas Health Science Center at Tyler, UT Health East Texas Level I Trauma Center, 11937 U.S. Highway 271, H252, Tyler, TX 75708. E-mail: [email protected].
